Data Sheet

Product Name:	SRPKIN-1
Cat. No.:	CS-0066697
CAS No.:	2089226-94-6
Molecular Formula:	$C_{27}H_{21}FN_2O_3S$
Molecular Weight:	472.53
Target:	SRPK
Pathway:	Cell Cycle/DNA Damage
Solubility:	DMSO : ≥ 110 mg/mL (232.79 mM)



BIOLOGICAL ACTIVITY:

SRPKIN-1 is a covalent and irreversible **SRPK1/2** inhibitor with **IC_{50}**s of 35.6 and 98 nM, respectively. Anti-angiogenesis effect[1]. IC50 & Target: IC50: 35.6 nM (SRPK1), 98 nM (SRPK2)[1] **In Vitro:** SRPKIN-1 treatment at 200 nM (10, 50, 100, 200 nM, 16 hours) significantly reduces SR protein phosphorylation at the steady state with or without washout[1].

SRPK-IN-1 potently converts VEGF from pro-angiogenic to anti-angiogenic isoform[1].

In Vivo: SRPKIN-1 (50 nM, 300 nM,1 μL, 5 times) blocks angiogenesis in a CNV mouse model through VEGF alternative splicing[1].

References:

[1]. Hatcher JM, et al. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform. Cell Chem Biol. 2018 Apr 19;25(4):460-470.e6.

CAIndexNames:

Benzenesulfonyl fluoride,3-(3-cyano-9-ethyl-6,11-dihydro-6,6-dimethyl-11-oxo-5H-benzo[b]carbazol-8-yl)-

SMILES:

O=S(C1=CC=CC(C2=C(CC)C=C3C(C(C)(C)C(NC4=C5C=CC(C#N)=C4)=C5C3=O)=C2)=C1)(F)=O

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA